eli lilly oral glp-1 Medscape | Orforglipron, Lilly's investigational glucagon-like peptide 1 receptor agonist (GLP-1 RA), achieved positive phase 3 results for Lilly's Oral GLP-1 Orforglipron Delivers
Description
These agents mimic the action of naturally occurring incretin hormones released by the intestine in response to food intake
For example, since 2018, spending on Ozempic increased 34 times while spending on Trulicity increased 1.7 times, as shown in the graph below
Common bowel-related side effects include: Diarrhea : Reported in approximately 830% of patients, with higher rates typically seen with weight management doses compared to diabetes doses
Ask your provider about emerging research on GLP-1 benefits for skin health
Table of Contents: What are GLP-1 injections, and how do they work for weight loss
